NCT03963921 - Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

May 28, 2020

Study Completion Date

August 31, 2020

Conditions

NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

HepaStem

Heterologous human adult liver-derived progenitor cells

Trial Locations (13)

CUB Erasme, Brussels

Cliniques Universitaires St Luc, Brussels

"University Multiprofile Hospital for Active Treatment Tsaritsa Yoana - ISUL", Sofia

Multiprofile hospital for active treatment (MHAT) Sofia Military Medical Academy, Sofia

University Hospital Antwerp (UZA), Edegem

Trakia Park Hospital, Stara Zagora

UZ Gent, Ghent

Hospital General Universitario Gregorio Marañon, Madrid

Hospital Universitario Ramón y Cajal, Madrid

CHU Bordeaux, Bordeaux

Paul Brousse Hospital, Villejuif

Vall d'Hebron, Barcelona

Hospital de la Santa Creu i Sant Pau, Barcelona